WEST CHESTER, Pa., January 27, 2022--(BUSINESS WIRE)--Beth Altman, former managing partner at accounting firm KPMG LLP San Diego, has joined Papyrus Therapeutics Inc. as an independent director of the Company's Board of Directors and as Chair of the Audit Committee.
Beth has more than 27 years of experience in accounting, finance, management, business development, strategic planning and corporate governance. During her 25-year career at KPMG LLP, Altman led a team of more than 260 professionals to provide assurance, tax and advisory services to public and private companies spanning all industry sectors. She also served as the lead audit partner for numerous public and private companies, predominantly in the life sciences and technology sectors. Since her retirement from KPMG LLP in October 2019, she has served on the Board and the Audit Committee of Allscripts Healthcare Inc., and Alphatec Holdings, Inc. and she has served on the Board and as Chair of the Audit Committee of CV Sciences, Inc.
She previously served as a board member of the Corporate Directors Forum, a 501 (c)(6) nonprofit organization focused on helping directors build more effective boards and held a leadership position in the Women Corporate Directors, San Diego Chapter, the world’s largest membership organization and community of today’s preeminent women leaders in business.
CEO Dr Paul Blake stated, "I am delighted that Beth is joining Papyrus Therapeutics. She has a deep experience of business, accounting, and finance, which coupled with her experience on the boards of other life science companies, will be of indispensable value to us as we expand our activities."
About Papyrus Therapeutics Inc.: Papyrus Therapeutics, Inc. (West Chester, PA, USA) is an emerging biopharma company developing novel tumor suppressor-based therapies. Papyrus´ lead therapeutic is a modified, recombinant version of Opioid Binding Protein/Cell Adhesion Molecule-like (OPCML). OPCML is a broadly acting tumor suppressor that is epigenetically silenced in many cancers, leading to tumor invasion and metastasis through deregulation of apoptosis, epithelial-to-mesenchymal transition (EMT) and cellular migration. Classic receptor tyrosine kinase [RTK] inhibition using small molecules has proven highly effective in many cancers, but treatment resistance remains a significant challenge. Delivery of OPCML, which works at the cell surface, can overcome this challenge by reconstituting normal RTK signaling in the tumor.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220127005015/en/
Dr Paul Blake
908 330 6997